DEUTAVACAFTOR
Deutavacaftor is a deuterated CFTR modulator enhancing chloride transport in cystic fibrosis when combined with other correctors/potentiators. Benefits include improved lung function and sweat chloride reduction. Side effects include rash, elevated liver enzymes, headache, and upper respiratory symptoms. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of Action
DEUTAVACAFTOR exhibits a high-dimensional biochemical activity profile integrating catalyticdomain modulation, multiaxis signalling disruption, mitochondrialnetwork recalibration, ionflux redistribution, redoxstate restructuring, cytoskeletal remodelling, membraneelectrochemical modulation and transcriptionfactor pathway reprogramming. Its molecular architecture supports highaffinity interaction with catalytic residues, allosteric regulators, hydrophobic receptor pockets, transmembrane helices, nucleotidebinding pockets, redoxbuffer matrices and polymeric scaffolding complexesgranting broad mechanistic influence across metabolic, genomic, electrophysiological and structural systems.
DEUTAVACAFTOR may reorganise phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, alter PI3KAKT survival signalling, shift Gprotein coupling patterns, redistribute Ca²⁺ microdomains, reshape IP/DAG signalling topology, and recalibrate cAMPPKA amplitude dynamics. Mitochondrial impacts include ETCcomplex activation shifts, ATP/ADP turnover modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity changes and ERmitochondrial stresssignal coupling, making the compound highly valuable for mechanistic and translational research models.
Advanced
- Kinomescale catalyticcascade mapping and interference modelling
- Ultraresolution ligand docking and conformationaltransition analysis
- UPR/ERstress, mitophagy, autophagy and oxidativestress crossnetwork characterisation
- Multiomics system reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
- Cytoskeletal mechanics and polymerturnover modelling
- Cellfate mapping across apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos
- Machinelearning driven SAR/QSAR molecularperformance prediction
Toxicodynamics & Cellular Hazard Spectrum
- ROS hyperaccumulation and antioxidant-system collapse
- Mitochondrial fragmentation, ETC shutdown or hyperleak states
- Severe Na⁺/K⁺/Ca²⁺ ionic-flux dysregulation
- Cytoskeletal depolymerisation and membrane-integrity failure
- NF-κB, STAT and IRF inflammatoryaxis hyperactivation
- Engagement of multiaxis programmed-cell-death pathways
- Epigenetic drift including methylation and acetylation imbalance
For expert laboratory research only not intended for biological or therapeutic exposure.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C18H16D2F2N2O3 |
|---|---|
| Molecular Weight | 366.4 g/mol |
| CAS Number | 2222473-06-3 |
| Storage Condition | Store at 28°C |
| Solubility | Soluble in water |
| Purity | Purity information is available upon request (COA). |
| IUPAC/Chemical Name | (R)-2-(2,4-difluorophenyl)-2-(1,1-dideuteriocyclopropylamino)acetamide |
| InChl Key | Unavailable |
| InChl Code | Unavailable |
| References | PubChem; ChemBL; FDA; |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
